An enzyme immunoassay was developed for the detection of human immunoglobulin M (IgM) antibody to different flavivirus antigens. The IgM antibody of human sera was selectively bound to anti-IgM antibodycoated solid-phase plates. Flavivirus IgM antibodies were then detected by use of various enzyme-labeled antigens. The flavivirus antigens (dengue type 2 virus, West Nile virus, and tick-borne encephalitis virus) were produced in suckling mice. The antigens were labeled with horseradish peroxidase by adding the activated enzyme at alkaline pH to sucrose-acetone-treated antigens. Addition of unlabeled mouse brain suspension of uninfected animals to the diluted enzyme-labeled antigens effectively reduced nonspecific binding to the solid phase. In patients with acute flavivirus infections, viral IgM antibody could be demonstrated with high sensitivity. Furthermore, the enzyme-labeled antigen-IgM test showed greater specificity than the hemagglutination inhibition test.
Only a few publications have appeared on the use of specific immunoglobulin M (IgM) antibody detection for the diagnosis of acute flavivirus infections. In early reports, specific IgM antibody activity was demonstrated in the IgM fraction isolated from serum specimens by ultracentrifugation; alternatively, the titer reduction of a serum sample was measured after mercaptoethanol treatment (5, 10) . Later, attempts were made to detect specific IgM antibody on plates coated with purified flavivirus antigens produced in tissue culture or in suckling mice (3, 7, 8, 11) . In 1978 and 1979, publications first appeared on the use of anti-IgMcoated microtiter plates for the detection of IgM antibody to hepatitis A (4, 6) and rubella (9) viruses. With these new test systems, human IgM antibody can be selectively bound to the coated solid phase. A crude viral antigen is then applied, followed by an appropriate indicator system, such as radiolabeled antibody (4, 6) or erythrocytes, if a hemagglutinating antigen is involved (9) . Recently, a similar test system was used for the detection of IgM antibodies to tick-borne encephalitis (TBE) virus (7) and Japanese B encaphalitis virus (1) . The tests improved the diagnosis of these flavivirus infections considerably. These reverse tests were further simplified by using enzyme-labeled antigen (ELA) . As shown with the detection of IgM and IgA antibodies to cytomegalovirus and Epstein-Barr virus (12, 14) , the ELAIgM method has the advantage offewer incubation steps and can be carried out in a shorter period of time. Also, a labeled hyperimmune antiserum is not required, and interaction of rheumatoid factor IgM with labeled immunoglobulin cannot occur. We, therefore, have tried to extend the ELA-IgM method to detect IgM antibodies to certain flavivirus antigens.
MATERIALS AND METHODS Labeling of flavivirus antigens. Dengue type 2 (New Guinea strain C) and type 3 (H87) viruses, West Nile virus, and TBE (strain Hyper) virus were propagated in suckling mice. Sucrose-acetone-extracted antigens were prepared according to Clarke and Casals (2) . The antigens agglutinated goose erythrocytes to a titer of at least 1:1,280 at pH 6.2.
For antigen labeling, a mixture of 1 ml of antigen at Coating of plates. Round-bottomed polystyrene microtiter plates were exposed to gamma-irradiation (2 mrads) before use, to improve the protein binding capacity. They were coated by adding 100 [LI per well of anti-human IgM (goat anti-human ,u-chain antibody, affinity chromatography purified; Medac, Hamburg, Federal Republic of Germany) at a dilution of 1:500 in phosphate-buffered saline, pH 7.5. The plates were stored at 4°C in a moist chamber and could be used after 2 days adsorption time. The plates could be lyophilized after deep-freezing (-20°C) and could be stored at room temperature after vacuum sealing in aluminumcoated plastic bags.
ELA-IgM test procedure. The plates were washed with buffer (0.15 M NaCl, 0.1 Tris [pH 7.5], 0.05% Tween 20, 0.1 mg of NaN3 per ml) as previously described (13) . Then 50 [lI of the serum specimens diluted in twofold steps from 1:100 through 1:12,800 in phosphate-buffered saline were incubated in eight wells for 2 h at room temperature. Also, two positive and three negative control sera diluted 1:100 were included in each assay. After another washing, ELA (50 ,u per well) was applied for a further 2 h at 4°C. After a final washing, the substrate (1 mg of o-phenylenediamine per ml in 0.1 M phosphate buffer [pH 6] plus 0.1% H202) was added, and the reaction was stopped with 2 M H2SO4 after 10 min. The test was read with a spectrophotometer at 495 nm.
Separation of IgM by ultracentrifugation in sucrose gradients. The sera (0.1 ml) were ultracentrifuged in an SW 41 rotor for 20 h at 180,000 x g. Before ultracentrifugation, the sera were stained by addition of fluorescein-isothiocyanate to permit direct visualization of the IgM band (13 Detection of neutralizing antibodies to dengue viruses. The dengue serotypes 1 through 4 (1, Hawaii; 2, New Guinea C; 3, H87; and 4, H241) were passaged in our laboratory in suckling mice. The method for detecting neutralizing antibodies in human sera followed that described by Shope and Sather (15) . Briefly, mixtures of virus suspensions (containing 10 and 100 50% lethal doses) and human sera (diluted 1:5) were incubated for 2 h at 37°C. For each dilution of virus and for each serotype, six suckling mice were inoculated. The suckling mice were observed daily, and 14 days after inoculation the neutralization index was determined.
SPIT. As an alternative for specific IgM antibody detection, the solid-phase immunosorbent technique (SPIT) of Krech and Wilhelm (9) was investigated. The initial steps of this method were identical to those of the ELA-IgM procedure (see above). Again the sera were incubated on the antiIgM-coated microtiter plates at dilutions of 1:100 up to 1:6,400 for 2 h. After washing, 2 U of hemagglutinating flavivirus antigen was applied overnight at 4°C, and after another washing a suspension of 0.1% goose erythrocytes was added in a mixture of 1 part of 0.4% bovine-albuminborate-saline (pH 9) and 1 part of the appropriate 0.2 M phosphate buffer (15 Generally, in the ELA-IgM test the P/N ratio (ratio of the optical density of a positive standard serum to that of a negative control pool) is mainly influenced by background reactions of the ELAs with the coated solid phase (12, 14) . To reduce this background, concentrated control antigen (normal mouse brain extract) was added to the diluted ELAs. This mixing of ELA and control antigen (see above) proved to be highly effective in reducing nonspecific reactions. For example, by addition of control antigen the P/N ratio in the dengue ELA-IgM test was increased from 2.5 to 8. Also, the presence of 1% Tween 20 in the ELA diluent improved the P/N ratio. For each ELA, the optimum test dilution had to be determined (11, 14) . As it happened, with all three antigens used maximum P/N ratios were obtained at a dilution of 1:100.
To define the cutoff level between negative and positive results, 100 sera of adult European patients without a history of recent flavivirus infection were examined with the ELAIgM tests. The arithmetic mean (m) of the optical densities of these control sera plus three standard deviations (m + 3s) was 0.14 for the two dengue ELAs, 0.12 for the West Nile ELA, and 0.12 for the TBE ELA. Moreover, we included the sera of 58 healthy refugees from Laos, 24 (41%) of which had dengue antibodies in the HI test. All sera were completely negative (cutoff levels < 0.13) in the dengue type 2, type 3, and West Nile ELA-IgM tests. Serum dilutions with optical densities exceeding the corresponding cutoff level were considered to be positive (12) . For the determination of the titration endpoint, twofold serum dilutions were applied in the ELA-IgM test. The highest dilution with an optical density still exceeding the cutoff level was defined as the IgM antibody titer (14) . The interassay variation was rather low in the ELA-IgM tests (variation coefficient < 36%; serum sample LI I; eight independent determinations with the dengue type 2, type 3, and West Nile ELAs).
In our nine patients with acute dengue fever ( Table 2 ) and in the four patients with TBE (Table 3) , specific IgM antibody was found in sera taken early after onset of the disease. IgM antibody titers ranged from 1:400 to 1:25,600 in sera of patients. A maximum P/N ratio of 15, corresponding to a titer of 25,600, was obtained with serum LI II ( Table 2) . Specific IgM antibody seemed to disappear several months after onset of the disease, whereas IgG titers persisted considerably longer. All ELA-IgM tests for IgM antibodies to dengue virus were carried out with two different dengue ELAs (prepared from dengue type 2 and type 3 virus antigens). However, significant differences in the antidengue IgM titers were not observed in the ELA-IgM test when the dengue type 2 ELA was substituted by the dengue type 3 ELA. Table 4 reflects the cross-reactivity of early dengue and TBE sera, using different flavivirus antigens in the HI and ELA-IgM tests. In the dengue group, the HI antibody titers to the closely related West Nile antigen were almost identical to the dengue HI titers, whereas antibody titers to the TBE antigen were considerably lower (usually one-fourth of the dengue HI titers). Most dengue patients had not only HI but also high IgM antibody titers to West Nile antigen, although exceptions were seen in three cases (SM, HE, and KO; Table 4 ). Here the much higher titers to dengue antigen seemed to support the suspected diagnosis of dengue fever. In contrast to the results of the HI test, in the ELA-IgM test the dengue sera did not show any cross-reactivity to TBE antigen.
On the other hand, the sera of the TBE patients ( As previously described (11, 13) , peroxidase-labeled antigens can be used with high efficiency for routine IgM antibody detection. An alternative method with unlabeled antigen and labeled antibody was described earlier (1, 3, 4, 6, 7) . With this latter method, relatively unpurified antigens can be used for IgM antibody detection, if the specific antigen is in turn detected by a labeled antibody of high specificity. Such highly specific antibodies might be obtained by hybridoma technology. On the other hand, the production of viral proteins by genetic engineering seems to become increasingly popular, which might favor the ELA production. Furthermore, the ELA-IgM test is less complicated and can be carried out more rapidly. Also, the ELA-IgM test is not influenced by the presence of rheumatoid factor, and it is less likely that rheumatoid factor will bind to a labeled antigen than to a labeled antibody or antibody fragment (12) . We were able to show here that extensive purification of the ELAs is not required, if an excess of unlabeled control antigen competes with the labeled host material in the ELA and unwanted anticellular reactivity is suppressed. By this approach further ELAs and ELA-IgM tests may easily be developed. In contrast to our TBE studies, our dengue tests were confined to patients from nonendemic areas. Therefore, the significance of the dengue or West Nile ELA-IgM tests for the diagnosis of acute flavivirus infections in endemic areas needs to be further investigated.
